Interestingly, galunisertib appeared to be more effective than the anti-LBP antibody in preventing GC-LM (Supplementary Fig. 7B), suggesting that galunisertib could inhibit GC-LM through an additional mechanism. Here, LBP is linked to gastric cancer.